Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gastrointestinal 1Breast 1

Conditions

Sarcoma 2Mesothelioma 2Lung Neoplasms 2Esophageal Neoplasms 2Thymus Neoplasms 1Sarcoma, Ewing 1Neoplasms, Germ Cell and Embryonal 1Kidney Neoplasms 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1Bone Neoplasms 1

Interventions

Oxaliplatin 3Irinotecan 3Surveys and Questionnaires 2Specimen Handling 2Radiosurgery 2Leucovorin 2Ketamine 2Hydroxychloroquine 2Fluorouracil 2Capecitabine 2ulixertinib 1tegafur-gimeracil-oteracil 1regorafenib 1pazopanib 1lanreotide 1fludarabine phosphate 1fludarabine 1dostarlimab 1dolasetron 1dexamethasone acetate 1dexamethasone 21-phosphate 1danvatirsen 1cobimetinib 1brivanib 1auricularum 1atezolizumab 1alectinib 1aldesleukin 1abelacimab 1Tomography, X-Ray Computed 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Gastrointestinal Neoplasms × Plicamycin × Clear all
NCT01624090 2019-12-30

Mithramycin for Lung, Esophagus, and Other Chest Cancers

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
16 enrolled 13 charts
BreastGastrointestinalOther solid neoplasmThoracic

Breast Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Lung Neoplasms, Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡